MOLN — MOLECULAR PARTNERS AG
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1745114 ·
Last close
$2.86
Market Cap
$109.55M
52W High
$5.36
52W Low
$2.63
ADV30
1,986
Next earnings
2026-08-25
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -12,061,000 | -11,708,000 | 64,515,000 | 57,493,000 | 13,853,000 |
| Jun 2026 | 0 | — | -13,591,000 | -13,561,000 | 75,698,000 | 67,930,000 | 17,154,000 |
| Mar 2026 | 0 | — | -13,443,000 | -13,144,000 | 87,658,000 | 64,251,000 | 19,206,000 |
| Dec 2025 | 0 | — | -12,667,000 | -12,649,000 | 102,107,000 | 82,653,000 | 21,773,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-46,691,000
Investing CF
$22,454,000
Financing CF
$-1,103,000
CapEx
$-714,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.34
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-344,072,000
Inventory
—
Receivables
$1,569,000
ST Investments
$0
EBIT TTM
$-51,034,000
Pretax Income TTM
$-51,058,000
Interest Exp TTM
$24,000
Analysts
5
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -55,436,000 | -61,651,000 | 102,107,000 | 21,773,000 | 80,334,000 | -51,257,000 |
| Dec 2024 | 4,970,000 | -61,217,000 | -54,043,000 | 158,528,000 | 16,891,000 | 141,637,000 | -59,248,000 |
| Dec 2023 | 7,038,000 | -61,108,000 | -61,984,000 | 198,352,000 | 21,923,000 | 176,429,000 | -59,005,000 |
| Dec 2022 | 189,556,000 | 116,613,000 | 117,853,000 | 262,258,000 | 27,092,000 | 235,166,000 | 118,566,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.17
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CMPX | Compass Therapeutics, Inc. | $109.26M | $0.61 | — |
| LENZ | LENZ Therapeutics, Inc. | $109.97M | $3.50 | — |
| CRDL | Cardiol Therapeutics Inc. | $113.53M | $0.97 | — |
| ENGN | enGene Therapeutics Inc. | $115.27M | $1.72 | — |
| ZURA | Zura Bio Ltd | $99.70M | $1.03 | — |
News headlines (Yahoo Finance, 1h cache)
Molecular Partners to Present at Inaugural UBS Global Biopharma Conference
2026-11-13 06:00 · Yahoo
Molecular Partners Presents New Preclinical Data for Next-Generation T Cell Engager MP0632 at SITC 2026
2026-11-06 06:00 · Yahoo
Molecular Partners to Present on DLL3-Targeting Radio-DARPin MP0712 at 2026 SNMMI Theranostics Conference and NACLC 2026
2026-11-05 06:00 · Yahoo
After Plunging 18.3% in 4 Weeks, Here's Why the Trend Might Reverse for Molecular Partners AG Sponsored ADR (MOLN)
2026-11-04 13:35 · Yahoo
Molecular Partners Reports Q3 2026 Financial Results, Deepens Focus on Targeted Radiotherapy
2026-10-29 06:00 · Yahoo
Molecular Partners Nominates MP0730 as Next Candidate in Expanding Pipeline of Radiotherapeutics, Targeting CD70
2026-10-22 05:00 · Yahoo
Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study
2026-08-25 05:00 · Yahoo
Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma
2026-07-16 05:00 · Yahoo
Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference
2026-07-15 05:00 · Yahoo
Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics
2026-07-06 05:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.